Molecular Biology of the Cell track citations

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

MBC in Press, published online ahead of print November 21, 2007
Mol. Biol. Cell 10.1091/mbc.E07-05-0433

A more recent version of this article appeared on February 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
E07-05-0433v1
19/2/457    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blish, K. R.
Right arrow Articles by Torti, S. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blish, K. R.
Right arrow Articles by Torti, S. V.

Submitted on May 11, 2007
Revised on October 19, 2007
Accepted on November 12, 2007

A Human Bone Morphogenetic Protein Antagonist is Down-Regulated in Renal Cancer

Kimberly Rose Blish,* Wei Wang,{dagger} Mark C. Willingham,{ddagger}{sect} Wei Du,{dagger} Charles E. Birse,||¶ Surekha R. Krishnan,|| Julie C. Brown,# Gregory A. Hawkins,{sect}@ A. Julian Garvin,{ddagger}{sect} Ralph B. D’Agostino Jr.,{sect}** Frank M. Torti,{dagger}{sect} and Suzy V. Torti{sect}#

*Section on Molecular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157-001; Departments of {dagger}Cancer Biology, {ddagger}Pathology, and #Biochemistry, **Department of Public Health Sciences, Section on Biostatistics, @Center for Human Genomics, and {sect}Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston-Salem, NC 27157-0001; ||Human Genome Sciences, Inc., Rockville, MD 20850

Monitoring Editor: Carl-Henrik Heldin

We analyzed expression of candidate genes encoding cell surface or secreted proteins in normal kidney and kidney cancer. This screen identified a BMP antagonist, SOSTDC1 (SclerOSTin Domain-Containing-1) as down-regulated in kidney tumors. To confirm screening results, we probed cDNA dot blots with SOSTDC1. SOSTDC1 message was decreased in 20/20 kidney tumors compared with normal kidney tissue. Immunohistochemistry confirmed significant decrease of SOSTDC1 protein in clear cell renal carcinomas relative to normal proximal renal tubule cells (p <0.001). Expression of SOSTDC1 was not decreased in papillary and chromophobe kidney tumors. SOSTDC1 was abundantly expressed in podocytes, distal tubules, and transitional epithelia of the normal kidney. Transfection experiments demonstrated that SOSTDC1 is secreted and binds to neighboring cells and/or the extracellular matrix. SOSTDC1 suppresses both BMP-7-induced phosphorylation of R-Smads-1, -5 and -8 and Wnt-3a signaling. Restoration of SOSTDC1 in renal clear carcinoma cells profoundly suppresses proliferation. Collectively, these results demonstrate that SOSTDC1 is expressed in the human kidney and decreased in renal clear cell carcinoma. Because SOSTDC1 suppresses proliferation of renal carcinoma cells, restoration of SOSTDC1 signaling may represent a novel target in treatment of renal clear cell carcinoma.

Present address: Celera Genomics Corporation, 45 W Gude Drive, Rockville, MD 20850-1159.

Address correspondence to: Suzy V. Torti (storti{at}wfubmc.edu)






Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Copyright © 2007 by The American Society for Cell Biology. Terms of copyright protection, warranties, and disclaimers.